Legend Biotech (LEGN) Event June 02, 2022, 19:24 UTC 10 1 comments (10% Negative) Legend Biotech (LEGN) Announces Clinical Development Update (Form 6-K) Comment Full text
Mereo BioPharma (MREO) Event June 02, 2022, 13:07 UTC 11 1 comments (85% Positive) Mereo BioPharma (MREO) Announces Clinical Development Update (Form 6-K) Comment Full text
Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE)) (AGLE) Event June 02, 2022, 13:03 UTC 12 1 comments (10% Negative) AEGLEA BIOTHERAPEUTICS, INC. (AGLE) Announces Clinical Trial Timeline Adjustment Comment Full text
Rallybio Corporation (RLYB) Event June 02, 2022, 13:00 UTC 12 1 comments (99% Positive) RALLYBIO CORPORATION (RLYB) Provides Update on years for helping to create Comment Full text
Cabaletta Bio Inc (CABA) Event June 02, 2022, 12:00 UTC 14 1 comments (99% Neutral) CABALETTA BIO, INC. (CABA) Files Form 8-K Comment Full text
Regeneron Pharmaceuticals Inc (REGN) Event June 02, 2022, 11:36 UTC 12 1 comments (70% Positive) REGENERON PHARMACEUTICALS, INC. (REGN) Announces Business Combination Comment Full text
Tonix Pharmaceuticals Holding Corp (TNXP) Event June 02, 2022, 11:05 UTC 12 1 comments (99% Neutral) TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Provides Business Update Comment Full text
Axsome Therapeutics Inc (AXSM) Event June 02, 2022, 11:05 UTC 12 1 comments (90% Positive) Axsome Therapeutics, Inc. (AXSM) Announces Enrollment Update for held Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment Comment Full text
Immunic Inc (IMUX) Event June 02, 2022, 10:45 UTC 12 1 comments (80% Positive) IMMUNIC, INC. (IMUX) Announces Enrollment Update for Million Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment Comment Full text
Centessa Pharmaceuticals plc (CNTA) Event June 02, 2022, 10:33 UTC 12 1 comments (75% Positive) CENTESSA PHARMACEUTICALS PLC (CNTA) Announces Clinical Development Update Comment Full text